AR
Antony Reshma
About Antony Reshma
Data last updated:
Antony Reshma is a Director at Jpo Global Business Solutions Private Limited (since 2021) and Designated Partner at Cinqmain Pharma Llp (since 2025). The companies operate in Business Services. The largest current company by reported revenue is Jpo Global Business Solutions Private Limited at ₹19 Lakh (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Jpo Global Business Solutions Private Limited U74999KL2021PTC068430 | Director | 06 Apr 2021 | 2021 | ₹19 Lakh (FY 2025) | Active |
| Cinqmain Pharma Llp ACN-2312 | Designated Partner | 30 Mar 2025 | 2025 | Active |
Board colleagues of Antony Reshma
| Name | DIN | Company | Designation |
|---|---|---|---|
| Juliet Johnson | 09135130 | Jpo Global Business Solutions Private Limited | Director |
| Nitha Poothara Joseph | 09135129 | Jpo Global Business Solutions Private Limited | Director |
| Lalmon Pathrose Pulickal | 11029849 | Cinqmain Pharma Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Antony Reshma
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antony Reshma
Antony Reshma currently holds 2 directorships: Jpo Global Business Solutions Private Limited (Director, since 06 Apr 2021, revenue ₹19 Lakh (FY 2025)); Cinqmain Pharma Llp (Designated Partner, since 30 Mar 2025).
Antony Reshma was first appointed on 06 Apr 2021 as Director at Jpo Global Business Solutions Private Limited. The most recent appointment on record is 30 Mar 2025 at Cinqmain Pharma Llp.
The current boards of Antony Reshma's companies include Juliet Johnson (Jpo Global Business Solutions Private Limited), Nitha Poothara Joseph (Jpo Global Business Solutions Private Limited), Lalmon Pathrose Pulickal (Cinqmain Pharma Llp).